Rapid COVID-19 Passive Therapy Response Platform

Informations projet

RapCo-19

N° de convention de subvention: 961845

DOI 10.3030/961845

Projet clôturé

Date de signature de la CE 28 Juillet 2020

Date de début 1 Septembre 2020

Date de fin 31 Mai 2022

Financé au titre de

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Coût total € 4 500 000,00

Contribution de l’UE € 2 500 000,00

Coordonné par

REMEDY BIOLOGICS LIMITED
Ireland

Livrables

Demonstrators, pilots, prototypes (3)

Proven pre-clinical safety and efficacy of the SARS-CoV-2 vaccine and antibody drug product

Preclinical studies demonstrating the safety and efficacy of passive therapy in rodent models Data will be shared with the EIC

Highly purified antibody therapy for preclinical studies

Characterised lead candidates will be expressed and antibody purified for the direct passive therapy in preclinical studies Sufficient purified antibodyprotein will be generated to ensure full preclinical studies can be performed

Antibody DNA sequence of lead candidate(s)

Recombinant antibody DNA and sequence information of lead candidates that can be provided to partners for cloningmanufacture in partner expression systems Providing recombinant DNA can provide rapid scaling through multiple partners

Open Research Data Pilot (1)

Deployment of SARS-Cov-2 antibody passive vaccine therapy

Remedy Biologics will partner with appropriate bigpharma and EU Government authorities to produce and deploy vaccines